WASHINGTON, D.C., November 5, 2020 - Baker Botts L.L.P. announced today that its client Merck & Co., Inc. (NYSE:MRK) has entered into a definitive agreement to acquire all outstanding shares of VelosBio for $2.75 billion in cash.
With the acquisition of VelosBio, a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies, Merck will bolster its position in the oncology and precision medicine pipeline. Merck’s press release can be found here.
The Baker Botts team was led by Antitrust Practice Co-Chair Stephen Weissman, special counsel Michael Bodosky and senior associate Matthew Adler. The firm’s antitrust team has represented Merck in a number of transactions over the past few years.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 700 lawyers practicing throughout a network of 13 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the technology, energy, and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.